Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Lung Cancer

  Free Subscription


Articles published in Oncologist

Retrieve available abstracts of 84 articles:
HTML format



Single Articles


    July 2022
  1. SAKURADA T, Nokihara H, Koga T, Zamami Y, et al
    Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study.
    Oncologist. 2022;27:e554-e560.
    PubMed     Abstract available


  2. WANG J, Martin-Romano P, Cassier P, Johnson M, et al
    Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation.
    Oncologist. 2022;27:536-e553.
    PubMed     Abstract available


  3. JAHANZEB M, Lin HM, Wu Y, Zhang P, et al
    Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
    Oncologist. 2022 Jul 4. pii: 6628677. doi: 10.1093.
    PubMed     Abstract available


    June 2022
  4. IKEDA S, Kato T, Kenmotsu H, Ogura T, et al
    Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study.
    Oncologist. 2022 Jun 27. pii: 6618634. doi: 10.1093.
    PubMed     Abstract available


  5. MACK PC, Klein MI, Ayers KL, Zhou X, et al
    Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
    Oncologist. 2022;27:476-486.
    PubMed     Abstract available


  6. GANTZER J, Davidson G, Vokshi B, Weingertner N, et al
    Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
    Oncologist. 2022;27:501-511.
    PubMed     Abstract available


    May 2022
  7. HUANG RSP, Harries L, Decker B, Hiemenz MC, et al
    Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
    Oncologist. 2022 May 22. pii: 6590419. doi: 10.1093.
    PubMed     Abstract available


  8. MURUGESAN K, Jin DX, Comment LA, Fabrizio D, et al
    Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer.
    Oncologist. 2022 May 22. pii: 6590420. doi: 10.1093.
    PubMed     Abstract available


  9. ISAWA T, Toi Y, Sugawara S, Taguri M, et al
    Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
    Oncologist. 2022;27:e410-e419.
    PubMed     Abstract available


    April 2022
  10. PASELLO G, Lorenzi M, Calvetti L, Oliani C, et al
    Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.
    Oncologist. 2022 Apr 16. pii: 6569250. doi: 10.1093.
    PubMed     Abstract available


  11. POPAT S, Hsia TC, Hung JY, Jung HA, et al
    Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
    Oncologist. 2022;27:255-265.
    PubMed     Abstract available


    March 2022
  12. LEMMON CA, Zabor EC, Pennell NA
    Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.
    Oncologist. 2022 Mar 14. pii: 6548144. doi: 10.1093.
    PubMed     Abstract available


  13. JIAN H, Wang K, Cheng Y, Ding L, et al
    Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2022;27:163-e213.
    PubMed     Abstract available


  14. TAN R, Yun C, Seetasith A, Sheinson D, et al
    Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer.
    Oncologist. 2022;27:236-243.
    PubMed     Abstract available


  15. WELLS JC, Sidhu A, Ding K, Smoragiewicz M, et al
    Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.
    Oncologist. 2022;27:e286-e293.
    PubMed     Abstract available


  16. STURGILL EG, Misch A, Jones CC, Luckett D, et al
    Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.
    Oncologist. 2022;27:175-182.
    PubMed     Abstract available


  17. LORENZI M, Ferro A, Cecere F, Scattolin D, et al
    First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
    Oncologist. 2022;27:87-e115.
    PubMed     Abstract available


  18. PENG W, Cao L, Chen L, Lin G, et al
    Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
    Oncologist. 2022;27:e116-e125.
    PubMed     Abstract available


  19. PAVAN A, Ferro A, Fortarezza F, Schiavon M, et al
    Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome.
    Oncologist. 2022;27:e199-e202.
    PubMed     Abstract available


    February 2022
  20. MORABITO A, Manzo A, Montanino A, Rachiglio AM, et al
    Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion.
    Oncologist. 2022;27:7-12.
    PubMed     Abstract available


  21. MOSKOVITZ M, Dudnik E, Shamai S, Rotenberg Y, et al
    ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.
    Oncologist. 2022;27:e76-e84.
    PubMed     Abstract available


  22. MIKKELSEN MK, Lund CM, Vinther A, Tolver A, et al
    Effects of a 12-Week Multimodal Exercise Intervention Among Older Patients with Advanced Cancer: Results from a Randomized Controlled Trial.
    Oncologist. 2022;27:67-78.
    PubMed     Abstract available


    December 2021
  23. LI J, Wang Q, Ge J, Tian Y, et al
    BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
    Oncologist. 2021;26:e2115-e2119.
    PubMed     Abstract available


  24. ARRIETA O, Lara-Mejia L, Bautista-GonzAlez E, Heredia D, et al
    Clinical Impact of the COVID-19 Pandemic in Mexican Patients with Thoracic Malignancies.
    Oncologist. 2021;26:1035-1043.
    PubMed     Abstract available


  25. OZA AM, Dubois F, Hegg R, Hernandez CA, et al
    A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors.
    Oncologist. 2021;26:e2254-e2264.
    PubMed     Abstract available


    November 2021
  26. PETRILLO LA, Zhou AZ, Sullivan R, Volandes A, et al
    Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer.
    Oncologist. 2021;26:e2090-e2093.
    PubMed     Abstract available


  27. AMELOT A
    Regarding "Surgical Metastasectomy in the Spine: A Review Article".
    Oncologist. 2021;26:e2097.
    PubMed    


  28. ZHANG G, Xia P, Zhao S, Yuan L, et al
    Gefitinib Combined with Cetuximab for the Treatment of Lung Adenocarcinoma Harboring the EGFR-Intergenic Region (SEC61G) Fusion and EGFR Amplification.
    Oncologist. 2021;26:e1898-e1902.
    PubMed     Abstract available


    October 2021
  29. OSPINA AV, Bruges R, Mantilla W, Triana I, et al
    Impact of COVID-19 Infection on Patients with Cancer: Experience in a Latin American Country: The ACHOCC-19 Study.
    Oncologist. 2021;26:e1761-e1773.
    PubMed     Abstract available


  30. CHEN X, Sheikh K, Nakajima E, Lin CT, et al
    Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
    Oncologist. 2021;26:e1822-e1832.
    PubMed     Abstract available


  31. GAN HK, Millward M, Jalving M, Garrido-Laguna I, et al
    A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors.
    Oncologist. 2021;26:e1844-e1853.
    PubMed     Abstract available


    September 2021
  32. MINCHOM A, Tan AC, Massarelli E, Subbiah V, et al
    Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-small Cell Lung Cancer in the Phase 1/2 LIBRETTO-001 Trial.
    Oncologist. 2021 Sep 15. doi: 10.1002/onco.13976.
    PubMed     Abstract available


  33. ARAI D, Sato T, Nakachi I, Fujisawa D, et al
    Longitudinal Assessment of Prognostic Understanding in Advanced Lung Cancer Patients and Its Association with Their Psychological Distress.
    Oncologist. 2021 Sep 12. doi: 10.1002/onco.13973.
    PubMed     Abstract available


  34. GOSSLING GCL, Chedid MF, Pereira FS, da Silva RK, et al
    Outcomes and Prognostic Factors of Patients with Metastatic Colorectal Cancer Who Underwent Pulmonary Metastasectomy with Curative Intent: A Brazilian Experience.
    Oncologist. 2021;26:e1581-e1588.
    PubMed     Abstract available


    August 2021
  35. LIN S, Luo S, Gu D, Li M, et al
    First-line durvalumab in addition to etoposide and platinum for extensive-stage small cell lung cancer: a United States-based cost-effectiveness analysis.
    Oncologist. 2021 Aug 25. doi: 10.1002/onco.13954.
    PubMed     Abstract available


  36. LORENZI M, Ferro A, Cecere F, Scattolin D, et al
    First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
    Oncologist. 2021 Aug 23. doi: 10.1002/onco.13951.
    PubMed     Abstract available


  37. XIANG M, Yang X, Ren S, Du F, et al
    Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.
    Oncologist. 2021 Aug 22. doi: 10.1002/onco.13950.
    PubMed     Abstract available


    July 2021
  38. IVANOVIC M, Knez L, Herzog A, Kovacevic M, et al
    Immunotherapy for metastatic non-small cell lung cancer: Real-world data from an academic Central and Eastern European centre.
    Oncologist. 2021 Jul 19. doi: 10.1002/onco.13909.
    PubMed     Abstract available


  39. LEE Y, Cho Y, Park EY, Park SY, et al
    One-step polymerase chain reaction-free nanowire-based plasma cell-free DNA assay to detect EML4-ALK fusion and to monitor resistance in lung cancer.
    Oncologist. 2021 Jul 17. doi: 10.1002/onco.13902.
    PubMed     Abstract available


  40. TJONG MC, Doherty M, Tan H, Chan WC, et al
    Province-Wide Analysis of Patient Reported Outcomes for Stage IV Non-Small Cell Lung Cancer.
    Oncologist. 2021 Jul 3. doi: 10.1002/onco.13890.
    PubMed     Abstract available


  41. GRAY J, Thompson JC, Carpenter EL, Elkhouly E, et al
    Plasma cell-free DNA genotyping-from an emerging concept to a standard-of-care tool in metastatic non-small cell lung cancer.
    Oncologist. 2021 Jul 3. doi: 10.1002/onco.13889.
    PubMed     Abstract available


  42. GEORGE S, Bell EJ, Zheng Y, Kim R, et al
    The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
    Oncologist. 2021;26:e1205-e1215.
    PubMed     Abstract available


  43. AYERS KL, Mullaney T, Zhou X, Liu JJ, et al
    Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
    Oncologist. 2021;26:e1226-e1239.
    PubMed     Abstract available


    June 2021
  44. LOI M, Alifano M, Scorsetti M, Nuyttens JJ, et al
    Judging a Fish by Its Ability to Climb a Tree? A Call for Novel Endpoints in the Appraisal of Ablative Local Treatments of Oligometastatic Cancer.
    Oncologist. 2021;26:e1085-e1086.
    PubMed    


  45. VARLOTTO JM, Sun Z, Ky B, Upshaw J, et al
    A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study.
    Oncologist. 2021;26:523-532.
    PubMed     Abstract available


    May 2021
  46. ALKREKSHI A, Tamaskar I
    Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection.
    Oncologist. 2021;26:e827-e830.
    PubMed     Abstract available


  47. MIYAGAWA C, Takaya H, Sakai K, Nishio K, et al
    A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review.
    Oncologist. 2021;26:356-361.
    PubMed     Abstract available


    April 2021
  48. KRUG K, Bossert J, Deis N, Krisam J, et al
    Effects of an interprofessional communication approach on support needs, quality of life and mood of advanced lung cancer patients: a randomized trial.
    Oncologist. 2021 Apr 16. doi: 10.1002/onco.13790.
    PubMed     Abstract available


  49. PERAVALI M, Ahn J, Chen K, Rao S, et al
    Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small-Cell Lung Cancer.
    Oncologist. 2021 Apr 12. doi: 10.1002/onco.13787.
    PubMed     Abstract available


  50. BERNICKER EH, Xiao Y, Abraham A, Yang B, et al
    Adherence to NCCN ALK testing guidelines for patients with advanced non-small cell lung cancer in US Community Medical Centers.
    Oncologist. 2021 Apr 6. doi: 10.1002/onco.13779.
    PubMed     Abstract available


  51. JELINEK MJ, Aggarwal C
    Adjuvant Osimertinib: A New Standard of Care.
    Oncologist. 2021;26:263-265.
    PubMed    


  52. VAN BRUMMELEN EMJ, Huijberts S, van Herpen C, Desar I, et al
    Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
    Oncologist. 2021;26:290-e545.
    PubMed     Abstract available


  53. JIAO XD, Liu K, Xu M, Yu G, et al
    Metastatic Low-Grade Sarcoma with CARS-ALK Fusion Dramatically Responded to Multiple ALK Tyrosine Kinase Inhibitors: A Case Report with Comprehensive Genomic Analysis.
    Oncologist. 2021;26:e524-e529.
    PubMed     Abstract available


    March 2021
  54. BANDYOPADHYAY A, Sharma S, Behera D, Singh N, et al
    UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
    Oncologist. 2021 Mar 16. doi: 10.1002/onco.13757.
    PubMed     Abstract available


  55. MATHIEU L, Shah S, Pai-Scherf L, Larkins E, et al
    FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
    Oncologist. 2021 Mar 9. doi: 10.1002/onco.13752.
    PubMed     Abstract available


  56. RODRIGUEZ-ANTOLIN C, Rosas-Alonso R, Cruz P, Higuera O, et al
    Novel SLC12A2-ROS1 fusion in non-small-cell lung cancer with a significant response to crizotinib: the importance of choosing the appropriate next-generation sequencing assay.
    Oncologist. 2021 Mar 8. doi: 10.1002/onco.13745.
    PubMed     Abstract available


  57. FRASS M, Lechleitner P, Grundling C, Pirker C, et al
    Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.
    Oncologist. 2021;26:e523.
    PubMed    


  58. ROSS JS, Sokol ES, Moch H, Mileshkin L, et al
    Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
    Oncologist. 2021;26:e394-e402.
    PubMed     Abstract available


  59. WANG Y, Chen Z, Han X, Li J, et al
    Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
    Oncologist. 2021;26:178-181.
    PubMed     Abstract available


    January 2021
  60. DURBIN SM, Zubiri L, Niemierko A, Bardia A, et al
    Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.
    Oncologist. 2021;26:49-55.
    PubMed     Abstract available


  61. CADRANEL J, Liu SV, Duruisseaux M, Branden E, et al
    Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
    Oncologist. 2021;26:7-16.
    PubMed     Abstract available


    November 2020
  62. SCHENK EL, Patil T, Pacheco J, Bunn PA Jr, et al
    2020 Innovation Based Optimism for Lung Cancer Outcomes.
    Oncologist. 2020 Nov 11. doi: 10.1002/onco.13590.
    PubMed     Abstract available


  63. POPAT S, Navani N, Kerr KM, Smit EF, et al
    Navigating diagnostic and treatment decisions in non-small-cell lung cancer: expert commentary on the multidisciplinary team approach.
    Oncologist. 2020 Nov 3. doi: 10.1002/onco.13586.
    PubMed     Abstract available


    October 2020
  64. HOLLEN PJ, Gralla RJ, Gentzler RD, Hall RD, et al
    Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation.
    Oncologist. 2020 Oct 23. doi: 10.1002/onco.13571.
    PubMed     Abstract available


  65. FRASS M, Lechleitner P, Grundling C, Pirker C, et al
    Homeopathic Treatment as an 'Add on' Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.
    Oncologist. 2020 Oct 3. doi: 10.1002/onco.13548.
    PubMed     Abstract available


  66. LE X, Heymach JV
    New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung Cancer.
    Oncologist. 2020;25:822-825.
    PubMed     Abstract available


    September 2020
  67. SEHGAL K, Rangachari D, VanderLaan PA, Kobayashi SS, et al
    Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.
    Oncologist. 2020 Sep 24. doi: 10.1002/onco.13537.
    PubMed     Abstract available


  68. WONG ML, Gao J, Thanarajasingam G, Sloan JA, et al
    Expanding beyond maximum grade: Chemotherapy toxicity over time by age and performance status in advanced non-small cell lung cancer in CALGB 9730 (Alliance A151729).
    Oncologist. 2020 Sep 20. doi: 10.1002/onco.13527.
    PubMed     Abstract available


  69. HAYASHI H, Niwa T, Yokoyama T, Tanizaki J, et al
    Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2020 Sep 12. doi: 10.1002/ONCO.13524.
    PubMed     Abstract available


    August 2020
  70. MELOSKY B, Cheema PK, Brade A, McLeod D, et al
    Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
    Oncologist. 2020 Aug 29. doi: 10.1634/theoncologist.2020-0193.
    PubMed     Abstract available


    July 2020
  71. NOSAKI K, Yamanaka T, Hamada A, Shiraishi Y, et al
    Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).
    Oncologist. 2020 Jul 12. doi: 10.1634/theoncologist.2020-0640.
    PubMed     Abstract available


  72. JOHN A, Shah RA, Wong WB, Schneider CE, et al
    Value of Precision Medicine in Advanced Non-Small Cell Lung Cancer: Real-World Outcomes Associated With the Use of Companion Diagnostics.
    Oncologist. 2020 Jul 6. doi: 10.1634/theoncologist.2019-0864.
    PubMed     Abstract available


  73. MILBURY K, Li Y, Durrani S, Liao Z, et al
    A Mindfulness-Based Intervention as a Supportive Care Strategy for Patients with Metastatic Non-Small Cell Lung Cancer and their Spouses: Results of a 3-Arm Pilot Randomized Controlled Trial.
    Oncologist. 2020 Jul 4. doi: 10.1634/theoncologist.2020-0125.
    PubMed     Abstract available


    June 2020
  74. NAKAMURA A, Tanaka H, Saito R, Suzuki A, et al
    Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).
    Oncologist. 2020 Jun 19. doi: 10.1634/theoncologist.2020-0545.
    PubMed     Abstract available


  75. ITCHINS M, Lau B, Hudson AL, Westman H, et al
    ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling.
    Oncologist. 2020 Jun 18. doi: 10.1634/theoncologist.2020-0075.
    PubMed     Abstract available


  76. BONANNO L, Pavan A, Ferro A, Calvetti L, et al
    Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.
    Oncologist. 2020 Jun 18. doi: 10.1634/theoncologist.2020-0148.
    PubMed     Abstract available


  77. YU Z, Xu Z, He Z, Lai J, et al
    Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial.
    Oncologist. 2020 Jun 13. doi: 10.1634/theoncologist.2020-0519.
    PubMed     Abstract available


  78. JAHANZEB M, Lin HM, Pan X, Yin Y, et al
    Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
    Oncologist. 2020 Jun 3. doi: 10.1634/theoncologist.2020-0011.
    PubMed     Abstract available


    May 2020
  79. TAKAYAMA K, Takeshita M, Inoue K, Ichiki M, et al
    Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801.
    Oncologist. 2020 May 9. doi: 10.1634/theoncologist.2020-0322.
    PubMed     Abstract available


    April 2020
  80. CHOI H, Pennell NA
    Exploring Ways to Improve Access to and Minimize Risk from Lung Cancer Screening.
    Oncologist. 2020 Apr 9. doi: 10.1634/theoncologist.2020-0149.
    PubMed    


  81. LIU Y, Hu X, Jiang J, Yang L, et al
    A Prospective Study of Apatinib in Patients with Extensive-Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy.
    Oncologist. 2020 Apr 6. doi: 10.1634/theoncologist.2019-0391.
    PubMed     Abstract available


  82. AKAMATSU H, Murakami E, Oyanagi J, Shibaki R, et al
    Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2020;25:e679-e683.
    PubMed     Abstract available


  83. IWAMA E, Goto Y, Murakami H, Tsumura S, et al
    Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.
    Oncologist. 2020;25:306-e618.
    PubMed     Abstract available


    March 2020
  84. POPAT V, Lu R, Ahmed M, Park JY, et al
    Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Oncologist. 2020 Mar 31. doi: 10.1634/theoncologist.2019-0814.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: